BNTX — BioNTech SE

—
Nasdaq · Health Care · Biotechnology · CIK 1776985 ·
Last close
$99.08
Market Cap
$24.89B
52W High
$124.00
52W Low
$79.52
ADV30
1,447,173
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 105,600,000 8,600,000 -938,700,000 -820,800,000 20,342,600,000 9,741,000,000 2,585,100,000
Mar 2026 118,100,000 46,700,000 -677,500,000 -531,900,000 21,074,100,000 9,939,400,000 2,376,300,000
Dec 2025 907,400,000 574,100,000 -280,500,000 -305,000,000 21,988,600,000 7,675,400,000 2,764,400,000
Sep 2025 1,518,900,000 1,370,600,000 653,900,000 -28,700,000 21,341,100,000 10,092,900,000 2,863,800,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$679,700,000
Investing CF
$-1,100,400,000
Financing CF
$-107,900,000
CapEx
$-235,000,000
Dividends Paid
—
Buybacks
$-129,200,000
EPS Diluted TTM
$-6.71
As of
2026-08-09

Balance + Analyst (yfinance extras)

Retained Earnings
$16,609,200,000
Inventory
$100,600,000
Receivables
$245,200,000
ST Investments
$5,037,800,000
EBIT TTM
$-1,441,800,000
Pretax Income TTM
$-1,629,500,000
Interest Exp TTM
$14,900,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$2,649,999,872
EBITDA
$-1,380,800,000
Free Cash Flow
$-249,562,496
Enterprise Value
$11,151,198,208
Total Cash
$13,463,900,160
Total Debt
$316,100,000
Shares Out
251,204,366
Trailing EPS
$-7.81
Book Value
$82.23
ROE
-9.3%
ROA
-5.4%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 2,869,900,000 -640,700,000 -1,136,100,000 21,988,600,000 2,764,400,000 19,224,200,000 456,000,000
Dec 2024 2,751,100,000 -709,400,000 -665,300,000 22,529,700,000 3,118,600,000 19,411,100,000 207,700,000
Dec 2023 3,819,000,000 875,600,000 930,300,000 23,006,300,000 2,760,400,000 20,245,900,000 5,371,400,000
Dec 2022 17,310,600,000 12,303,800,000 9,434,400,000 23,279,100,000 3,223,500,000 20,055,600,000 13,577,400,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.69

Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)

max pain strike: $100.00 · spot: $99.08 · call volume: 1,381 · put volume: 449
Expected Move to 2026-10-16: ±$8.21 (8.29%) — implied range $90.87 – $107.29 · ATM straddle on $100.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BIIB BIOGEN INC. $33.79B $228.69 —
EXEL EXELIXIS, INC. $14.46B $58.37 —
RVMD Revolution Medicines, Inc. $43.24B $201.74 —
NBIX NEUROCRINE BIOSCIENCES INC $14.28B $140.44 —
HALO HALOZYME THERAPEUTICS, INC. $12.81B $112.89 —

News headlines (Yahoo Finance, 1h cache)

How New Lung Cancer Data And Updated COVID Shot At BioNTech (BNTX) Has Changed Its Investment Story
2026-09-27 01:10 · Yahoo
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
2026-09-24 20:27 · Yahoo
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines
2026-09-23 21:30 · Yahoo
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up?
2026-09-22 14:51 · Yahoo
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test.
2026-09-21 18:38 · Yahoo
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
2026-09-21 15:45 · Yahoo
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
2026-09-17 13:50 · Yahoo
Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?
2026-09-16 22:13 · Yahoo
BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain?
2026-09-16 19:08 · Yahoo
BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
2026-09-15 14:37 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.